A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma

• DOI: 10.1016/j.intimp.2022.108846
• Publication Date: 2022-07-08T14:27:13Z
• Authors: Yongsheng Huang; Jianwei Liao; Faya Liang; Peiliang Lin; Sangqing Wu; Yuchu Ye; Ming Gao; Renhui Chen; Haicang Zeng; Xinke Yin; Yuanling Jiang; Nengtai Ouyang; Ping Han; Xiaoming Huang
• Keywords: Immune checkpoint; Targeted Therapy

Tumor mutation burden high (TMB-H) is widely used in the guidance of immune checkpoint blocking (ICB) therapy for head and neck squamous cell carcinoma (HNSCC) patients. However, a few patients still had a poor response. Therefore, it is necessary to investigate a better model to guide ICB therapy. We constructed a genomic mutation model conducive to ICB therapy using an available HNSCC dataset. Moreover, treatment procedures for patients with HNSCC from our internal cohort confirmed this model. Here, a genomic mutation signature based on a list of 25 candidate genes that are favorable for immunotherapy was established. Patients with combined mutation had a respectable clinical outcome under ICB treatment. Notably, compared with patients who obtained TMB-H (TMB ≥ 10, but did not have combined mutation), those patients with TMB-L (TMB < 10) and combined mutation acquired remarkably beneficial overall survival. Moreover, the combined mutation signature predicting the survival status of patients was superior to TMB, with a Youden index of 0.55. Furthermore, higher immune cell infiltration levels, more active cancer-immunity cycle activities and immune response pathways were observed in patients with combined mutation. Finally, our internal cohort further confirmed that combined mutated patients can benefit from ICB therapy rather than any other patients.